Haematological Malignancies, Leukaemia
Read Time: 4 mins

The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease – Focusing on the Opinions of CML-treating Physicians

Copy Link
Published Online: Jun 8th 2017 European Oncology and Haematology, 2017;13(1):15–6 DOI:
Authors: Ahmet Emre Eskazan
Quick Links:
Article Information

Although the management of patients with chronic myeloid leukaemia in chronic phase (CML-CP), especially in the newlydiagnosed patient, is generally straightforward, it may vary in the salvage setting, since some of the currently approved tyrosine kinase inhibitors are not available in some countries. This commentary mainly focuses on a questionnaire and the subsequent paper, which were performed in order to understand the perspectives of the CML-treating physicians from different countries in the management of refractory CML-CP.


Chronic myeloid leukaemia, bosutinib, dasatinib, imatinib, nilotinib, ponatinib, refractory, tyrosine kinase inhibitor


Imatinib (Gleevec®, Novartis Pharmaceutical Corporation, New Jersey, US) is a BCR-ABL1 tyrosine kinase inhibitor (TKI) that has dramatically improved the outcome of patients with chronic myeloid leukaemia in chronic phase (CML-CP).1 Although most of the patients with CML-CP do well under imatinib, approximately 40% of them stop receiving imatinib due to lack of efficacy and/or because of intolerance. In the imatinib arm of the International Randomized Study of Interferon and STI571 (IRIS) trial, 34% of patients were no longer on the study drug at 6 years, for reasons that included lack of efficacy (12%) and the occurrence of adverse events (AEs) (4%).2 Nearly 20% of the patients develop resistance (both primary and acquired),3 and BCR-ABL1 kinase domain (KD) mutations are detected in approximately 50% of patients with treatment failure and progression.4

There are various treatment options available for CML patients who remain refractory to the prior line(s) of TKI treatment.5,6 In patients who fail upfront imatinib therapy, second generation TKIs (2GTKIs; dasatinib, nilotinib and bosutinib) can be administered.7–9 In addition to 2GTKIs, ponatinib (Iclusig®; Ariad Pharmaceuticals, Massachusetts, US) is a potent TKI active against native and mutated forms of BCR-ABL1, including T315I, and it was approved after the phase II PACE study demonstrating that ponatinib was highly active in heavily pretreated Philadelphia chromosome-positive leukaemia patients.10

Although having some differences between each other, in the recommendations of European LeukemiaNet (ELN),4 the guidelines of National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO),11,12 there are evidence-based suggestions in order to harmonise the response evaluation and the management of patients with CML both in the upfront and salvage settings.

In this issue of European Oncology and Haematology, Prof Hughes and Prof Saglio summarised the treatment options in patients with CML-CP who failed prior TKIs including alternative TKI treatments and allogeneic haematopoietic stem-cell transplantation (allo-HSCT), and then primarily focusing on a questionnaire which was completed by 14 physicians from different countries.13 The purpose of the questionnaire and the subsequent paper was to understand the perspectives of the CML-treating physicians in the management of refractory CML-CP.

The questionnaire had three sections. In the first section, the consensus responses to four questions mainly focusing on both BCR/ABL1-dependent and BCR/ABL1-independent resistance mechanisms; the difference in the rates of T315I mutation between daily practice and clinical trials; cross-intolerance between different TKIs; and solutions in order to address poor adherence to TKI treatment. The management of AEs, and patient education were also shared.13

In the second part of the questionnaire, the respondents were asked about strategies to combat failure/intolerance to previous 2GTKIs.13 The participants agreed that the chance of achieving a response was much higher in case of intolerance, but patients still have the chance to obtain improved responses after switching to another 2GTKI due to resistance. While choosing another 2GTKI, mutational status and comorbidities of each patient, together with the toxicity profile of the TKI should be taken into consideration.14,15 The respondents also concluded that bosutinib (Bosulif®; Pfizer, New York, US) can be a reasonable treatment modality if there is intolerance to one or more 2GTKI; although, there are some toxicities observed with bosutinib (e.g., diarrhoea) at the dose of 500 mg/day. Additionally, bosutinib has not yet been approved in many countries.

In the second section, the participants were also asked about the role of ponatinib in the management of patients of CML-CP after failing previous lines TKIs. All the participants agreed that a patient with T315I should receive ponatinib regardless of their molecular response.13 Also, nearly all respondents reported that they would not give ponatinib to patients in CML-CP after imatinib failure, unless the patient harbours T315I mutation. But in case of failure to imatinib in a patient with advanced disease, 83% of the participants agreed that ponatinib could be a reasonable choice of treatment.13 Nearly 70% of the respondents agreed that ponatinib could be suitable in patients failing two lines of TKIs; however, there were fewer participants (7/12, 58%) who thought that ponatinib would be an option in patients who had resistance or intolerance to prior two lines of TKI treatments. More than half of the respondents (7/12, 58%) stated that they would not choose ponatinib in the second-line setting in a patient who failed dasatinib or nilotinib as an upfront treatment.

Regarding the role of allo-HSCT, 67% of the respondents agreed that after ponatinib failure, allo-HSCT is the right treatment option.13 Approximately 60% of the physicians would not go for an allograft without trying ponatinib, and all the respondents agreed that allo-HSCT would be appropriate in a patient who is in second CP.13

In the last part of the questionnaire, the consensus responses regarding four questions were displayed.13 The participants revealed that although bosutinib has a limited role in the third- or fourth-lines of TKI therapy, nevertheless, this drug can be still chosen over ponatinib in patients with known risks of cardiovascular events, where there is intolerance to prior TKIs, and in cases who are resistant to two or more lines of TKI treatment without harbouring any mutations.13 In the management of patients who progressed to advanced disease during a TKI treatment, the respondents listed various treatment modalities including the dose escalation of the current TKI, switching to an appropriate TKI, choosing ponatinib in case of T315I mutation, adding conventional chemotherapy to TKI, and allografting in the suitable patient.

Although the management of CML-CP, especially in the newly-diagnosed patient, is generally straightforward, it may vary in the salvage setting, since some of the currently approved TKIs in the management of CML are not available in some countries. This survey in which the management strategies of refractory CML was discussed, does have a value, but obviously has various limitations as concluded by Prof Hughes and Prof Saglio. The new ELN recommendations, which will be published soon, hopefully will address some of the conflicts underlined both in the survey and within this paper, in order to harmonise the management of refractory disease.

Article Information:

Ahmet Emre Eskazan has received honoraria from Novartis and Bristol-Myers Squibb. No funding has been received for the publication of this article. This article is a short opinion piece and has not been submitted to external peer reviewers but was reviewed by the editorial board for accuracy before publication.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.


Ahmet Emre Eskazan, Istanbul University, Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Fatih, Istanbul, Turkey. E:


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.




1. Sahin F, Saydam G, Cömert M, et al., Turkish chronic myeloid leukemia study: retrospective sectional analysis of CML patients, Turk J Haematol, 2013;30:351–8.
2. Hochhaus A, O’Brien SG, Guilhot F, et al., Six year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia, 2009;23:1054–61.
3. O’Hare T, Eide CA, Deininger MW, Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure or chronic myeloid leukemia, Blood, 2007;110:2242–9.
4. Baccarani M, Deininger MW, Rosti G, et al., European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, Blood, 2013;122:872–84.
5. Keskin D, Eskazan AE, The treatment of chronic myeloid leukaemia (CML) in the era of tyrosine kinase inhibitors - what is new in the battle of CML?, European Oncology & Haematology, 2015;11:30–1.
6. Pasic I, Lipton JH, Current approach to the treatment of chronic myeloid leukaemia, Leuk Res, 2017;55:65–78.
7. Hochhaus A, Kantarjian HM, Baccarani M, et al., Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy, Blood, 2007;109:2303–9.
8. Kantarjian HM, Giles F, Gattermann N, et al., Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance, Blood, 2007;110:3540–6.
9. Khoury HJ, Cortes JE, Kantarjian HM, et al., Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure, Blood, 2012;119:3403–12.
10. Cortes JE, Kim DW, Pinilla-Ibarz J, et al., A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias, N Engl J Med, 2013;369:1783–96.
11. O’Brien S, Radich JP, Abboud CN, et al., Chronic myelogenous leukemia, version 1.2015, J Natl Compr Canc Netw, 2014;12:1590–610.
12. Baccarani M, Pileri S, Steegmann JL, et al., Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2012;23(Suppl 7):vii72–7.
13. Hughes T, Saglio G, Expert opinion on the treatment of refractory phronic phase chronic myeloid leukaemia, European Oncology & Haematology, 2017;13:Epub ahead of print.
14. Keskin D, Sadri S, Eskazan AE, Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations, Drug Des Devel Ther, 2016;10:3355–61.
15. Kirkizlar O, Eskazan AE, Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia, Expert Review of Quality of Life in Cancer Care, 2016;1:353–9.

Further Resources

Share this Article
Related Content In Leukaemia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72